ESMO 2020 Highlights on adjuvant osimertinib for EGFR mutated NSCLC: The ADAURA study

Highlights on amivantamab after progression on osimertinib in EGFR-mutated NSCLC: MARIPOSA-2Подробнее

ASCO 2023 Highlights on adjuvant osimertinib in resected EGFR mutated NSCLC: The ADAURA trialПодробнее

ADAURA: osimertinib adjuvant therapy in EGFR mutated NSCLCПодробнее

ADAURA: osimertinib adjuvant therapy on CNS disease recurrenceПодробнее

ESMO 2020 lung cancer highlightsПодробнее

Osimertinib adjuvant therapy in patients with early stage EGFR mutated NSCLC after tumour resectionПодробнее

ESMO 2020 Highlights on durability of clinical benefit and biomarkers with AMG510 in NSCLCПодробнее

ADAURA: the benefit of adjuvant osimertinibПодробнее

ESMO 2020 Highlights on 1st line lorlatinib for ALK+ NSCLC: The CROWN StudyПодробнее

Dr. Levy on the DFS Benefit Achieved With Adjuvant Osimertinib in EGFR+ NSCLCПодробнее

Highlights from ESMO 2020Подробнее

Alex Spira, MD, PhD, FACP, on the practice-changing potential of the ADAURA study from ESMO 2020Подробнее

ESMO 2020 Highlights on pembrolizumab as 1st line therapy for aUC: The KEYNOTE-361 studyПодробнее

Reflections on the ADAURA studyПодробнее

Lung cancer highlights from ESMO 2022Подробнее

ADAURA results: Adjuvant osimertinib for EGFRm non-small cell lung cancerПодробнее

ESMO 2020 ADAURA Tsuboi, Castro e HaradaTV Onconews 200920Подробнее

ESMO 2020: Lung cancer latestПодробнее